Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
168 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Escherichia coli Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Escherichia coli Infections - Pipeline Review, H1 2016', provides an overview of the Escherichia coli Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections - The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects - The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Escherichia coli Infections Overview 10 Therapeutics Development 11 Pipeline Products for Escherichia coli Infections - Overview 11 Pipeline Products for Escherichia coli Infections - Comparative Analysis 12 Escherichia coli Infections - Therapeutics under Development by Companies 13 Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 15 Escherichia coli Infections - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Escherichia coli Infections - Products under Development by Companies 18 Escherichia coli Infections - Products under Investigation by Universities/Institutes 21 Escherichia coli Infections - Companies Involved in Therapeutics Development 22 Adenium Biotech ApS 22 Arsanis Biosciences GmbH 23 AstraZeneca Plc 24 AvidBiotics Corp. 25 Bioorganic Research and Services S.A. 26 Cellceutix Corporation 27 Cytovation AS 28 Debiopharm International SA 29 Emergent BioSolutions Inc. 30 F. Hoffmann-La Roche Ltd. 31 GangaGen Inc. 32 GlaxoSmithKline Plc 33 Johnson & Johnson 34 Melinta Therapeutics, Inc 35 Microbiotix, Inc. 36 MicuRx Pharmaceuticals, Inc. 37 Nabriva Therapeutics AG 38 Navigen Pharmaceuticals, Inc. 39 Nosopharm SAS 40 Novabiotics Limited 41 Omnia Molecular Ltd. 42 Pherecydes Pharma SA 43 Phico Therapeutics Limited 44 Procarta Biosystems Limited 45 Sealife PHARMA GMBH 46 Sequoia Sciences, Inc. 47 Soligenix, Inc. 48 Syntiron LLC 49 Tetraphase Pharmaceuticals Inc. 50 Varinel, Inc. 51 Visterra, Inc. 52 Escherichia coli Infections - Therapeutics Assessment 53 Assessment by Monotherapy Products 53 Assessment by Target 54 Assessment by Mechanism of Action 56 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 A-3APO - Drug Profile 62 AA-139 - Drug Profile 64 ASN-4 - Drug Profile 65 AvR2-V10 - Drug Profile 66 BC-7634 - Drug Profile 68 BC-9074 - Drug Profile 69 BC-9529 - Drug Profile 70 BC-9563 - Drug Profile 71 BIZ-20131 - Drug Profile 72 BIZ-20132 - Drug Profile 73 BIZ-20133 - Drug Profile 74 BNT-006 - Drug Profile 75 CC-1807 - Drug Profile 76 CyPep-1 - Drug Profile 77 Debio-1454 - Drug Profile 78 Drugs for Bacterial Infections - Drug Profile 79 dusquetide - Drug Profile 80 EcoXyn-4V - Drug Profile 82 Escherichia coli (whole cell) vaccine - Drug Profile 83 Escherichia coli vaccine - Drug Profile 84 Escherichia coli vaccine - Drug Profile 85 ETEC vaccine - Drug Profile 86 EV-035 - Drug Profile 87 GN snare - Drug Profile 89 GN-4474 - Drug Profile 90 INX-201 - Drug Profile 91 JNJ-63871860 - Drug Profile 92 LTA-001 - Drug Profile 94 MBX-2319 - Drug Profile 95 MDN-0057 - Drug Profile 96 MRX-V - Drug Profile 98 NBTI-5463 - Drug Profile 99 NOSO-95179 - Drug Profile 100 NP-432 - Drug Profile 101 Onc-72 - Drug Profile 102 P-100031 - Drug Profile 103 Peptides for Infectious Diseases - Drug Profile 104 PMX-100 - Drug Profile 105 PMX-1091 - Drug Profile 106 PMX-1142 - Drug Profile 107 PMX-1241 - Drug Profile 108 PMX-1278 - Drug Profile 109 PMX-1363 - Drug Profile 110 PMX-1405 - Drug Profile 111 PMX-223 - Drug Profile 112 PMX-229 - Drug Profile 113 PMX-247 - Drug Profile 114 PMX-633 - Drug Profile 115 PMX-668 - Drug Profile 116 PMX-693 - Drug Profile 117 PMX-843 - Drug Profile 118 PP-0121 - Drug Profile 119 Proteins for Infectious Diseases - Drug Profile 121 PT-4 - Drug Profile 122 Recombinant Protein for Escherichia Coli Infections - Drug Profile 123 RX-05 - Drug Profile 124 RXP-873 - Drug Profile 125 SE-1 - Drug Profile 126 Shigetec - Drug Profile 127 SLP-0901 - Drug Profile 128 SLP-0905 - Drug Profile 129 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 130 Small Molecule for Malaria and Bacterial Infections - Drug Profile 131 Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 132 Small Molecules for Bacterial Infections - Drug Profile 133 Small Molecules for Escherichia Coli Infections - Drug Profile 134 Small Molecules for Escherichia coli Infections - Drug Profile 135 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 136 Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 137 Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 138 Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 139 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 140 Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 141 Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 142 Synthetic Peptides for Escherichia Coli Infections - Drug Profile 143 TP-6076 - Drug Profile 144 VAR-10100 - Drug Profile 145 VIS-GMN - Drug Profile 146 Escherichia coli Infections - Recent Pipeline Updates 147 Escherichia coli Infections - Dormant Projects 157 Escherichia coli Infections - Discontinued Products 160 Escherichia coli Infections - Product Development Milestones 161 Featured News & Press Releases 161 Appendix 162 Methodology 162 Coverage 162 Secondary Research 162 Primary Research 162 Expert Panel Validation 162 Contact Us 162 Disclaimer 163
List of Tables
Number of Products under Development for Escherichia coli Infections, H1 2016 16 Number of Products under Development for Escherichia coli Infections - Comparative Analysis, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Number of Products under Development by Companies, H1 2016 (Contd..1) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Clinical Stage Development, H1 2016 21 Comparative Analysis by Early Stage Development, H1 2016 22 Products under Development by Companies, H1 2016 23 Products under Development by Companies, H1 2016 (Contd..1) 24 Products under Development by Companies, H1 2016 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2016 26 Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H1 2016 27 Escherichia coli Infections - Pipeline by Arsanis Biosciences GmbH, H1 2016 28 Escherichia coli Infections - Pipeline by AstraZeneca Plc, H1 2016 29 Escherichia coli Infections - Pipeline by AvidBiotics Corp., H1 2016 30 Escherichia coli Infections - Pipeline by Bioorganic Research and Services S.A., H1 2016 31 Escherichia coli Infections - Pipeline by Cellceutix Corporation, H1 2016 32 Escherichia coli Infections - Pipeline by Cytovation AS, H1 2016 33 Escherichia coli Infections - Pipeline by Debiopharm International SA , H1 2016 34 Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 35 Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 36 Escherichia coli Infections - Pipeline by GangaGen Inc., H1 2016 37 Escherichia coli Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 38 Escherichia coli Infections - Pipeline by Johnson & Johnson, H1 2016 39 Escherichia coli Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 40 Escherichia coli Infections - Pipeline by Microbiotix, Inc., H1 2016 41 Escherichia coli Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 42 Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H1 2016 43 Escherichia coli Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 44 Escherichia coli Infections - Pipeline by Nosopharm SAS, H1 2016 45 Escherichia coli Infections - Pipeline by Novabiotics Limited, H1 2016 46 Escherichia coli Infections - Pipeline by Omnia Molecular Ltd., H1 2016 47 Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H1 2016 48 Escherichia coli Infections - Pipeline by Phico Therapeutics Limited, H1 2016 49 Escherichia coli Infections - Pipeline by Procarta Biosystems Limited, H1 2016 50 Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 51 Escherichia coli Infections - Pipeline by Sequoia Sciences, Inc., H1 2016 52 Escherichia coli Infections - Pipeline by Soligenix, Inc., H1 2016 53 Escherichia coli Infections - Pipeline by Syntiron LLC, H1 2016 54 Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 55 Escherichia coli Infections - Pipeline by Varinel, Inc., H1 2016 56 Escherichia coli Infections - Pipeline by Visterra, Inc., H1 2016 57 Assessment by Monotherapy Products, H1 2016 58 Number of Products by Stage and Target, H1 2016 60 Number of Products by Stage and Mechanism of Action, H1 2016 62 Number of Products by Stage and Route of Administration, H1 2016 64 Number of Products by Stage and Molecule Type, H1 2016 66 Escherichia coli Infections Therapeutics - Recent Pipeline Updates, H1 2016 152 Escherichia coli Infections - Dormant Projects, H1 2016 162 Escherichia coli Infections - Dormant Projects (Contd..1), H1 2016 163 Escherichia coli Infections - Dormant Projects (Contd..2), H1 2016 164 Escherichia coli Infections - Discontinued Products, H1 2016 165
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
